2024-511110-21-00RecruitingPhase 1
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 3 Jul 2024
- Start date
- 9 Sept 2024
- Lead sponsor
- F. Hoffmann-La Roche AG
- Diseases
- Parkinson disease
- EU CT number
- 2024-511110-21-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 150
- 10 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medizinische Universitaet Innsbruck | Innsbruck | Austria | Not yet recruiting |
| Brain Research Center Amsterdam B.V. | Amsterdam | Netherlands | Recruiting |
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Recruiting |
| Radboud universitair medisch centrum Stichting | Nijmegen | Netherlands | Recruiting |
| Brain Research Center Den Bosch B.V. | 's-Hertogenbosch | Netherlands | Recruiting |
| Brain Research Center Zwolle B.V. | Zwolle | Netherlands | Recruiting |
| Sahlgrenska University Hospital-Vaestra Goetalandsregionen | Goteborg | Sweden | Not yet recruiting |
| Karolinska University Hospital | Huddinge | Sweden | Not yet recruiting |
| Region Skane Skanes Universitetssjukhus | Lund | Sweden | Not yet recruiting |
| CTC Clinical Trial Consultants AB | Uppsala | Sweden | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.